- Home
- NMI vs COYA Comparison
NMI vs COYA Comparison
Compare NMI & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$3.96
Company Overview
Basic Information| Metric | NMI | COYA |
|---|---|---|
| Founded | N/A | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.9M | 126.6M |
| IPO Year | 1995 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NMI | COYA |
|---|---|---|
| Price | $9.91 | $3.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.80 |
| AVG Volume (30 Days) | 29.6K | ★ 113.8K |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $820.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $9.21 | $3.94 |
| 52 Week High | $10.85 | $7.75 |
Technical Indicators
Market Signals| Indicator | NMI | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 30.73 |
| Support Level | $9.86 | $3.94 |
| Resistance Level | $10.05 | $5.16 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 24.86 | 8.73 |
Price Performance
Historical Comparison NMI
COYA
About NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income exempt from federal income tax, which it seeks to achieve by investing mainly in a diversified portfolio of tax-exempt municipal obligations.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.